FAMDF (FAMDF) Stock Price & Analysis
FAMDF (FAMDF) rose 0.00% to USD 0.02 as of July 25, 2026 at 13:44 UTC, according to Nexqual real-time market data.
FAMDF last closed at USD 0.02; the session ranged USD 0–0 on volume of 250 shares. Market capitalization is $10.99M, with a 52-week range of USD 0–0.2 (PNK). Source: Nexqual, July 25, 2026 at 13:44 UTC.
Key Statistics (as of July 25, 2026 at 13:44 UTC)
| Price | USD 0.02 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.02 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0.2 |
| Volume | 250 shares |
| Market Cap | $10.99M |
| Exchange | PNK |
Technical Analysis (FAMDF)
Nexqual's technical model rates FAMDF "BUY" based on 5 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 13:44 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 54.83 (neutral) |
| vs SMA50 | Above (USD 0.01) |
| MACD | 0 (positive) |
Analyst Ratings (FAMDF)
Wall Street analysts rate FAMDF "None", per Nexqual as of July 25, 2026 at 13:44 UTC.
| Consensus Rating | None |
|---|
Earnings (FAMDF)
Source: Nexqual, July 25, 2026 at 13:44 UTC.
Financials & Fundamentals (FAMDF)
| Total Revenue | $1.70M |
|---|---|
| Revenue Growth (YoY) | -90.00% |
| Gross Margin | +73.08% |
| Operating Margin | -342.88% |
| Profit Margin | +0.00% |
| ROE | -154.16% |
| Current Ratio | 2.06 |
| Total Cash | $3.40M |
| Total Debt | $0 |
| Free Cash Flow | $-4.88M |
Source: Nexqual, July 25, 2026 at 13:44 UTC.
Financial Health Score (FAMDF)
Nexqual rates FAMDF's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 13:44 UTC.
| Growth | Strong — Revenue +349% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $3M cash, no debt |
| Cash Flow | Weak — FCF negative: -$5M, burning cash |
| Efficiency | Critical — ROE -154%, ROA -60.5% |
Ownership (FAMDF)
| Insider Ownership | +16.13% |
|---|---|
| Institutional Ownership | +11.85% |
| Shares Outstanding | 581.33M |
| Float | 531.03M |
Source: Nexqual, July 25, 2026 at 13:44 UTC.
Leadership (FAMDF)
FAMDF is led by Alexander James Hanbury Duggan (age 55), CEO & Executive Director, per Nexqual as of July 25, 2026 at 13:44 UTC.
| CEO & Executive Director | Alexander James Hanbury Duggan (age 55) |
|---|---|
| COO, Finance Director, Company Secretary & Executive Director | Angela Hildreth (age 45) |
| Head of R & D & Executive Director | Kenneth William James (age 73) |
| Chief Scientific Officer & Adviser to the Board | William Duncan Potter BSc (Hons), MSc (age 77) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ACHFF | Arch Biopartners Inc. | USD 0.61 | ▲ 0.17% |
| SEOVF | SERNOVA BIOTHERAPEUTICS INC. | USD 0.08 | ▲ 0% |
| SRBCF | Sirona Biochem Corp. | USD 0.01 | ▲ 0% |
| KNBIF | Kane Biotech Inc. | USD 0.02 | ▲ 0% |
| IDGXF | INTEGRATED DIAGNOSTICS HLDGS PL | USD 0.49 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 13:44 UTC. This page is informational and not investment advice.